Revenue: As of FY2026 Q1, the actual value is USD 10.84 M, beating the estimate of USD 4.05 M.EPS: As of FY2026 Q1, the actual value is USD -0.75, missing the estimate of USD -0.655.EBIT: As of FY2026 Q1, the actual value is USD -9.763 M.<h4>Revenue</h4>Precision BioSciences, Inc. reported total revenues of $10.8 million for the first quarter of 2026, a significant increase compared to $29 thousand for the first quarter of 2025. This rise was primarily driven by milestone revenue recognized under a license agreement with TG Therapeutics, Inc. and a legacy ARCUS agriculture gene editing collaboration agreement.<h4>Operating Expenses</h4><ul><li>Research and Development (R&amp;D) Expenses: R&amp;D expenses were $13.1 million for the first quarter of 2026, a slight decrease from $13.6 million for the same period in 2025, representing a $0.5 million decrease mainly due to reductions in platform development and research expenses.</li><li>General and Administrative (G&amp;A) Expenses: G&amp;A expenses decreased to $6.8 million for the first quarter of 2026 from $8.6 million in the prior year’s quarter, a $1.8 million reduction resulting from operational discipline and lower employee-related costs.</li><li>Total Operating Expenses: Total operating expenses for the quarter were $19.913 million, down from $22.141 million in the first quarter of 2025.</li></ul><h4>Operating Loss</h4>Precision BioSciences, Inc. reported an operating loss of - $9.075 million for the first quarter of 2026, an improvement from an operating loss of - $22.112 million for the first quarter of 2025.<h4>Other (Expense) Income</h4>Total other expense was - $9.366 million for the first quarter of 2026, a decrease of $10.9 million compared to total other income of $1.547 million for the first quarter of 2025, primarily due to non-cash fair value adjustments and a decrease in interest income. Gain from equity method investment: There was no gain recognized from equity method investment in Q1 2026, compared to a $1.342 million gain in Q1 2025. Loss on changes in other fair value adjustments: This resulted in a loss of - $2.951 million in Q1 2026, compared to a gain of $0.049 million in Q1 2025. Loss on change in fair value of warrant liability: This loss was - $7.107 million in Q1 2026, compared to - $0.804 million in Q1 2025. Interest expense: Interest expense was - $0.311 million in Q1 2026, compared to - $0.354 million in Q1 2025. Interest income: Interest income was $0.999 million in Q1 2026, compared to $1.323 million in Q1 2025. Gain (loss) on disposal of assets: This resulted in a gain of $0.004 million in Q1 2026, compared to a loss of - $0.009 million in Q1 2025.<h4>Net Loss</h4>Net loss for the first quarter of 2026 was - $18.4 million, an improvement from a net loss of - $20.6 million for the first quarter of 2025.<h4>Balance Sheet Data (as of March 31, 2026)</h4><ul><li>Cash, Cash Equivalents, and Restricted Cash: Precision BioSciences, Inc. held approximately $125.8 million as of March 31, 2026, down from $137.153 million as of December 31, 2025.</li><li>Working Capital: Working capital was $100.938 million as of March 31, 2026, compared to $109.827 million as of December 31, 2025.</li><li>Total Assets: Total assets were $143.891 million as of March 31, 2026, compared to $154.416 million as of December 31, 2025.</li><li>Total Liabilities: Total liabilities were $67.790 million as of March 31, 2026, compared to $62.168 million as of December 31, 2025.</li><li>Total Stockholders’ Equity: Total stockholders’ equity was $76.101 million as of March 31, 2026, compared to $92.248 million as of December 31, 2025.</li></ul><h4>Operational Metrics</h4><ul><li>PBGENE-HBV: Precision BioSciences, Inc. has treated 16 patients with 38 administrations of PBGENE-HBV across five cohorts in the ELIMINATE-B trial. A late-breaking poster presentation for PBGENE-HBV was accepted for the EASL Congress 2026, and Clinical Trial Application approval was received to expand ELIMINATE-B into France and Romania.</li><li>PBGENE-DMD: Following U.S. FDA IND clearance, Precision BioSciences, Inc. activated Arkansas Children’s Hospital as the first clinical trial site and is actively enrolling patients in the Phase 1⁄2 FUNCTION-DMD clinical trial. The PBGENE-DMD program received FDA Fast Track designation in March 2026.</li><li>Partnered Programs: iECURE, Inc. is expected to present clinical data from the OTC-HOPE trial in May 2026. Imugene Limited’s Azer-Cel was selected for oral presentation at the 2026 ASCO Annual Meeting, and Precision BioSciences, Inc. received a $7.5 million clinical milestone payment from TG Therapeutics, Inc. for Azer-Cel in progressive multiple sclerosis.</li></ul><h4>Outlook / Guidance</h4>Precision BioSciences, Inc. expects its current cash and cash equivalents, alongside fiscal and operating discipline and its at-the-market (ATM) facility, to fund its cash runway through 2028. The company believes it is sufficiently capitalized to achieve key data milestones for its PBGENE-HBV and PBGENE-DMD programs through 2028. Additionally, Precision BioSciences, Inc. anticipates sharing further clinical data from the PBGENE-HBV program at hepatitis-focused medical conferences throughout 2026 and expects initial patient screening for PBGENE-HBV in France and Romania during the second quarter of 2026.

Precision Biosciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 10.84 M